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Dyslipidemia is a major contributor to cardiovascular morbidity and mortality. Although awareness of
the importance of the risk of dyslipidemia has increased, treatment of dyslipidemia has not improved
accordingly. Even though the actual number of individuals receiving treatment has increased, the pro-
portion of those who are treated but did not reach the recommended treatment goal, is still disturbing.
This problem is highlighted in this issue of Atherosclerosis by the article of S. Zhao et al. who in a cross-
sectional study involving 25,697 Chinese individuals found that overall 38.5% of those receiving lipid-
lowering treatment did not achieve the treatment goal for low density lipoprotein. Of particular concern
is the authors' ﬁnding that the majority of these were individuals with a high cardiovascular risk and/or
with type 2 diabetes mellitus. Some of the main reasons for this problem relate to patients' compliance
with treatment and inertia on the side of physicians and patients to increase the dose of a given
medication or move to a combination treatment. New medications with various and different phar-
macological modes of actions and increased possibility for combination treatment may help to improve
the treatment for dyslipidemia.
© 2014 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Cardiovascular diseases are still a major cause for mortality in
the U.S. and world wide [1]. Dyslipidemia represents a major
contributor to cardiovascular risk [2]. A great number of studies
have shown that treatment of dyslipidemia, in particular lowering
of low density lipoprotein (LDL) cholesterol, reduces cardiovascular
morbidity and mortality signiﬁcantly [3].
Statins are the cornerstone of lipid-lowering treatment [4]. Several
different typesof statinswithdifferentpharmacological structures are
now available as well as a number of other lipid-lowering drugs.
However, despite the availability of thiswide choice of lipid-lowering
drugs, plasma lipid levels, particularly those of LDL often are not
optimally lowered to reach the recommended level [5].
In a previous issue of Atherosclerosis, Shuiping Zhao et al. report
the results of a large cross-sectional study conducted in China and
which included 25,697 patients with cardiovascular or cerebro-
vascular disease and/or type 2 diabetes mellitus who were treated
for lipid abnormalities [6]. One particular aspect that the authors
investigated was the number of patients who did not achieve the
treatment target level for LDL cholesterol according to the Chinese
Guidelines for the Management of Dyslipidemias. They found that.atherosclerosis.2014.05.916.
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which is similar to the results from other studies [7,8].
Some aspects reported in this study are noteworthy and impor-
tant and highlight a common problem in the day to day medical
practice. The percentage of patients who did not reach the LDL
cholesterolwashighest in thosepatientswhomtheauthors classiﬁed
as high and very high risk; more than half of these patients did not
achieve the goal level of LDL cholesterol. The reasons for this are, as
the authors pointed out, multifactorial. This includes factors seen in
the treatment forother chronicdiseases aswell suchashypertension,
diabetes, and are mainly a problem of compliance to the prescribed
medicationsor inertia on thepart of the treatingphysician. This point
is highlighted in this study as well. Ninety-eight percent of the pa-
tientswere onmonotherapy (89% on statins)which includedmost of
the patients at high or very high risk. Increases in the dose of statins
were done least in these groups of patients. However, an interesting
ﬁnding in this study was that quadrupling the dose of statins,
expressed as simvastatin equivalents, did not result in an increased
percentage of patients reaching the LDL cholesterol goal. This aspect
seems to require some further exploration.
These results also show that there is a need for an improvement
in the treatment of dyslipidemia and to overcome common prob-
lems such as compliance and dose adjustments. However, it also
shows a need for more combination treatment particularly in high
risk patients. Since statins are the mainstay for lowering lipids
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statins are necessary. Ezetimibe is effective, safe and well tolerated
in combination with statins [9], its effectiveness being to some
extent genetically determined [10]. Fibrates present another option
for combination treatment although less frequently used and
greater possibility for side effects. Evolocumab promises to be a
very effective lipid lowering drug with a different mode of action
given as monotherapy as well as in combination with statins [11].
Most of the recommendations or guidelines for the treatment of
dyslipidemias focus on LDL cholesterol as the primary target for
lipid control. Secondary targets such as high density cholesterol
(HDL) and/or non-HDL cholesterol are reported but often not
included in the overall assessment of a patient's lipid proﬁle.
Fortunately, the authors of this article measured HDL cholesterol
and non-HDL cholesterol. Overall, the percentage of patients who
did not reach the goal for non-HDL cholesterol was similar to the
ones not reaching the goal for LDL cholesterol and also signiﬁcantly
greater in patients at very high cardiovascular risk. This ﬁnding is
not surprising and ismainly due to a lowHDL cholesterol, 31.9% and
40.8% had an HDL cholesterol below 1.0 mmol/L (men) or below
1.2 mmol/L (women). This indicates that non-HDL cholesterol
although not as widely studied as is LDL cholesterol, nevertheless
appears to be a good predictor for cardiovascular risk. Although
HDL cholesterol concentrations predict cardiovascular risk [12], it
has lost some of its role as a risk predictor mainly in part because
HDL particles are not homogenous and appear in different size and
shape with different concentrations phospholipids, cholesterol,
triglycerides and apolipoprotein A-1 [13].
As the authors correctly point out, the presence of diabetes
represents a major reason for patients not reaching the treatment
goal. Half of the patients who had a diagnosis of diabetes did not
reach the goal for the LDL cholesterol. This ﬁgure was even higher
(60.3%) in patients who had a diagnosis of coronary heart disease.
Similar results were found for non-HDL cholesterol. The main
reason for this problem again, is compliance with a further increase
in the number of medications since now, two treatment goals have
to be met: dyslipidemia and diabetes. As the authors correctly
pointed out, this problem becomes even more serious if it is asso-
ciated with obesity and development of the metabolic syndrome.
At this point, fatty tissue starts to function like an “endocrine” or-
gan secreting a number of hormones/cytokines that accelerates the
problem of dyslipidemia, diabetes and hypertension [14].
The basic message from this article is not entirely new but
strongly reﬂects serious treatment gaps in what the authorscorrectly describe as a “real life” environment. It emphasizes the
importance of meeting the recommended goals for lipid control
thereby achieving the desired reduction of risk for cardiovascular
morbidity and mortality.References
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